DiaMedica Therapeutics Inc.

NASDAQ:DMAC

Biotechnology

Healthcare
$8.59 -0.17%

-$0.01 today

Market cap
$463.49M
Beta
1.00
P/E (TTM)
-8.8
EPS (TTM)
-$0.65
52W Low $3.48High $10.42

Volume 0.21M

Average 0.19M

DMAC EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

DiaMedica Therapeutics Inc.NASDAQ: DMAC

EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026

EPS (Basic) remains negative

Q1 FY2026 EPS (Basic) was -$0.19, compared with -$0.18 a year earlier. Trailing-twelve-month EPS (Basic) was -$0.71.

Context

  • EPS (Basic) grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EPS (Basic) reaches the consensus estimate from 3 analysts of -$0.78 (-12.0%) for the fiscal year ending Dec 2026, a step up from the -16.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$0.19-11.8% QoQ
Last fiscal yearDec 2025
-$0.7-16.7% YoY
LTMMar 2026
-$0.71-10.9% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.6%-11.6%-6.1 pp
1 year-16.7%-12.0%+4.7 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Basic) history

USD · from the income statement

Latest · FY2025
(0.70) USD
Year-over-year change
-16.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Basic) vs competitors

How DMAC compares with its peers on the latest reported figures

  • DMAC's LTM Mar 2026 EPS (Basic) of -$0.71 is the 3rd highest of the 7 companies compared; the peer median is -$2.23.
  • Its year-over-year change of -10.9% is the 5th highest of 7, against a peer median of +3.5%.
DMAC Competitors Peer median
EPS (Basic) for DMAC and competitors
Company Period LTM YoY 3-year CAGR
AKBAAkebia Therapeutics, Inc.LTM Mar 2026-$0.08 +63.2%—
PROKProKidney Corp.LTM Mar 2026-$0.55 +8.3%—
DMACDiaMedica Therapeutics Inc.LTM Mar 2026-$0.71 -10.9%—
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026-$2.05 +12.2%—
BIOABioAge Labs, Inc.LTM Mar 2026-$2.4 -18.2%—
MAZEMaze Therapeutics, Inc.LTM Mar 2026-$2.75 -4396.9%—
DNLIDenali Therapeutics Inc.LTM Jun 2026-$2.84 -1.4%—
Peer median (excluding DMAC) -$2.23+3.5%—

Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development8.77M7.84M13.11M19.06M24.61M
Selling, General & Admin4.88M6.16M8.16M7.62M9.78M
Operating Expenses13.65M14M21.27M26.68M34.4M
Depreciation & Amortization24K25K30K39K43K
EBITDA(13.54M)(13.62M)(19.31M)(24.38M)(32.7M)
EBITDA Margin—————
Operating Income(13.65M)(14M)(21.27M)(26.68M)(34.4M)
Operating Margin—————
Interest Income0002.3M0
Interest Expense00000
Other Income / Expenses82K353K1.93M2.27M1.66M
Income Before Tax(13.56M)(13.65M)(19.34M)(24.41M)(32.74M)
Pre-Tax Margin—————
Income Tax Expense28K28K43K30K28K
Net Income(13.59M)(13.68M)(19.38M)(24.44M)(32.77M)
Net Margin—————
EPS (Basic)(0.65)(0.52)(0.60)(0.60)(0.70)
EPS (Diluted)(0.65)(0.52)(0.60)(0.60)(0.70)
Weighted Avg Shares20.77M26.44M32.57M40.4M46.98M
Weighted Avg Shares (Diluted)20.77M26.44M32.57M40.4M46.98M

DiaMedica Therapeutics Inc.

NASDAQ:DMAC

Intrinsic Alpha fair value

Locked

Current Price

$8.59

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.